ArticleBone marrow transplantation2018
Unmanipulated haploidentical transplantation conditioning with busulfan, cyclophosphamide and anti-thymoglobulin for adult severe aplastic anaemia.
Article in Bone marrow transplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Chinese Society of Hematology clinical practice guidelines for the comprehensive management of allogeneic hematopoietic stem cell transplantation in patients with severe aplastic anemia.Chinese medical journal · 2026Guideline
- Meta-analysis of the results of haploidentical transplantation in the treatment of aplastic anemia.Annals of hematology · 2023Pooled it
- Haploidentical hematopoietic stem cell transplantation in aplastic anemia: a systematic review and meta-analysis of clinical outcome on behalf of the severe aplastic anemia working party of the European group for blood and marrow transplantation (SAAWP of EBMT).Bone marrow transplantation · 2020Pooled it
- Comparison of Haploidentical Hematopoietic Stem Cell Transplant With or Without Unrelated Cord Blood Infusion in Severe Aplastic Anemia: Outcomes of a Multicenter Study.Frontiers in immunology · 2022Trial
- Up-front alternative donor HCT in severe aplastic anemia: gaps and opportunities to translate evidence into practice.Blood advances · 2025Review
- Successful haploidentical transplantation using plasma exchange and post-transplantation cyclophosphamide for severe aplastic anemia patients with anti-human leukocyte antigen donor-specific antibodies.Annals of hematology · 2021Article
- A novel TBI free conditioning protocol for haploidentical transplant in acquired aplastic anemia: (FluCAB-Prime).Bone marrow transplantation · 2021Article
- Haploidentical stem cell transplantation for aplastic anemia: the current advances and future challenges.Bone marrow transplantation · 2021Review
- CMV Infection and CMV-Specific Immune Reconstitution Following Haploidentical Stem Cell Transplantation: An Update.Frontiers in immunology · 2021Review
- Comparable Outcomes in Acquired Severe Aplastic Anemia Patients With Haploidentical Donor or Matched Related Donor Transplantation: A Retrospective Single-Center Experience.Frontiers in medicine · 2021Article
- Comparison of hemorrhagic and ischemic stroke after allogeneic hematopoietic stem cell transplantation.Bone marrow transplantation · 2020Article
- [How I treat refractory sever aplastic anemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020Article
- Current insights into the treatments of severe aplastic anemia in China.International journal of hematology · 2020Review
- Who is the best haploidentical donor for acquired severe aplastic anemia? Experience from a multicenter study.Journal of hematology & oncology · 2019Article
- Immunosuppressive therapy versus haploidentical transplantation in adults with acquired severe aplastic anemia.Bone marrow transplantation · 2019Article
- [Haploidentical allogenetic hematopoietic stem cell transplantation for X-linked adrenoleukodystrophy].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2019Article
- [Advances in haploidentical hematopoietic stem cell transplantation for non-malignant hematological diseases].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We conducted a retrospective analysis to evaluate outcomes of haploidentical transplantation in adult severe aplastic anaemia (SAA) patients. Fifty-one adults received haploidentical transplantation between May 2011 and December 2016. Patients were administered busulfan (Bu), cyclophosphamide (Cy) and anti-thymoglobulin (ATG) as conditioning regimens, followed by bone marrow and peripheral blood transplantation. The patients' median age was 25 years. Forty-nine patients survived for more than 28 days and all achieved donor myeloid engraftment. The median time for myeloid engraftment and platelet recovery was 13 days (range, 10-21) and 17.5 (range, 7-101) days. The cumulative incidence (CI) of grade II-IV and III-IV acute GvHD) was 20.00±0.33% and 6.00±0.12%, respectively. The incidence of chronic GvHD was 14.00±0.36% and 25.90±0.71%, and that of moderate-severe chronic GvHD was 2.51±0.06% and 6.92±0.25% at 1 and 3 years, respectively. The 3-year estimated overall survival and failure-free survival were both 83.5±5.4% with a median follow-up of 21.1 months. Multivariate analysis showed hematopoietic cell transplantation-specific comorbidity index (HCT-CI) score of ⩾3 was significantly associated with worse outcome. Haploidentical transplantation conditioning including Bu/Cy/ATG was a safe and effective strategy for adult SAA patients, and HCT-CI might be an outcome predictor in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.